Morepen Labs adds three new drugs – Rivaroxaban, Vildagliptin, UDCA to its API portfolio

MUMBAI, Oct 14:Morepen Laboratories has developed and added three blockbuster drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in domestic and global markets.
The three bulk drugs (APis) are Rivaroxa ban (trade name Xarelto), Vildagliptin (trade names – Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid).
While two products Rivaroxaban and Yildagliptin will augment Morepen’s presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment, company said in a filing with BSE.
The current global market size for Rivaroxaban, a powerful anticoagulant (blood thinner), is USD7.1 9 Billion (Rs. 51,000 cores) and that of Vildagliptin, which is a strong oral Anti-diabetic drug used for the treatment of type 2 diabetes, is USD1.28 Billion (Rs. 9,000 cores). The global market size for Rivaroxaban is likely to touch USD9.00 Billion(Rs. 64,000 crore) by year 2023 and that of Yildagliptin USD1.35 Billion (Rs. 9,600 crore) by 2021.
Morepen Labs will initially target patent free markets for these two drugs globally. The Drug Master File (DMF) for regulatory markets like US etc will be filed within the next 12 months’ time frame.
Mr Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd said. “The company has already built-up additional capacities and is now all set to commercially launch these three new API’s under its portfolio. Dedicated efforts of Morepen’s in-house R&D Centre at Baddi (Himachal Pradesh), which was recently approved by Department of Scientific & Industrial Research, Govt. of India, has led to the release of these three products,” he said.
“With a focus on new molecules, new patented processes, we now look forward towards investing more in our R&D Infrastructure for future growth of the company,” Mr. Suri further added.